Endo Pharma (ENDP) Posts Q3 EPS of $0.63, Misses By 1c; Guides
More News related to ENDP
- Endo to Present at Barclays Capital Global Healthcare Conference
- CORRECTING and REPLACING -- Quarterly Changes to the NASDAQ Q-50 Index
- Quarterly Changes to the NASDAQ Q-50 Index
- Endo Pharma (ENDP) Appoints Julie McHugh to COO
- Endo Pharmaceuticals Announces Appointment of New Chief Operating Officer
More News related to Earnings
- B. Riley Downgrades OPNET Technologies (OPNT) to Neutral
- Rodman & Renshaw Downgrades S&T Bancorp (STBA) to Market Perform
- Barrington Research Downgrades Somanetics (SMTS) to Market Perform
- Barrington Research Downgrades Hologic (HOLX) to Market Perform; More Favorable Risk/Reward in HAE
- OPNET (OPNT) Shares Falling as B. Riley Cuts to Neutral
Endo Pharmaceuticals (NASDAQ: ENDP) reports Q3 EPS of $0.63, versus the analyst estimate of $0.64. Revenue for the quarter was $361.03 million, which compares to the estimate of $365.33 million.
Raises FY09 Guidance to $1.44 - $1.465 billion., and FY09 adjusted EPS expected to be $2.67 - $2.73.
Related Categories
EarningsGuidance
Stocks Mentioned
-0.08Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
